Glenmark Life Sciences Limited

NSEI:GLS Stock Report

Market Cap: ₹132.7b

Glenmark Life Sciences Valuation

Is GLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLS (₹1080.05) is trading above our estimate of fair value (₹542.4)

Significantly Below Fair Value: GLS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLS?

Key metric: As GLS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GLS. This is calculated by dividing GLS's market cap by their current earnings.
What is GLS's PE Ratio?
PE Ratio31.2x
Earnings₹4.24b
Market Cap₹132.69b

Price to Earnings Ratio vs Peers

How does GLS's PE Ratio compare to its peers?

The above table shows the PE ratio for GLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average67x
532482 Granules India
27.1x22.1%₹133.7b
STAR Strides Pharma Science
78.1x45.6%₹128.0b
500674 Sanofi India
26.4x-2.6%₹141.6b
AETHER Aether Industries
136.3x44.8%₹109.8b
GLS Glenmark Life Sciences
31.2x23.4%₹132.7b

Price-To-Earnings vs Peers: GLS is good value based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (67x).

Price to Earnings Ratio vs Industry

How does GLS's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.78m
524652 Ind-Swift
2xn/aUS$13.52m
No more companies available in this PE range
GLS 31.2xIndustry Avg. 32.2xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GLS is good value based on its Price-To-Earnings Ratio (31.2x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is GLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.2x
Fair PE Ratio41.3x

Price-To-Earnings vs Fair Ratio: GLS is good value based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (41.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,080.05
₹1,138.60
+5.4%
9.2%₹1,295.00₹1,015.00n/a5
Nov ’25₹1,051.00
₹1,080.50
+2.8%
14.9%₹1,295.00₹790.00n/a6
Oct ’25₹1,123.30
₹1,084.33
-3.5%
16.0%₹1,295.00₹790.00n/a6
Sep ’25₹1,052.65
₹1,031.83
-2.0%
15.3%₹1,295.00₹790.00n/a6
Aug ’25₹902.70
₹989.33
+9.6%
10.9%₹1,150.00₹790.00n/a6
Jul ’25₹887.40
₹932.60
+5.1%
9.2%₹1,040.00₹790.00n/a5
Jun ’25₹836.25
₹932.60
+11.5%
9.2%₹1,040.00₹790.00n/a5
May ’25₹828.90
₹932.60
+12.5%
9.2%₹1,040.00₹790.00n/a5
Apr ’25₹785.05
₹874.67
+11.4%
8.9%₹940.00₹765.00n/a3
Mar ’25₹859.60
₹874.67
+1.8%
8.9%₹940.00₹765.00n/a3
Feb ’25₹856.70
₹874.67
+2.1%
8.9%₹940.00₹765.00n/a3
Jan ’25₹655.20
₹685.00
+4.5%
6.7%₹720.00₹620.00n/a3
Dec ’24₹636.90
₹685.00
+7.6%
6.7%₹720.00₹620.00n/a3
Nov ’24₹619.45
₹685.00
+10.6%
6.7%₹720.00₹620.00₹1,051.003
Oct ’24₹617.95
₹707.75
+14.5%
7.5%₹756.00₹620.00₹1,123.304
Sep ’24₹631.80
₹708.20
+12.1%
6.7%₹756.00₹620.00₹1,052.655
Aug ’24₹639.90
₹708.20
+10.7%
6.7%₹756.00₹620.00₹902.705
Jul ’24₹569.15
₹603.00
+5.9%
8.9%₹685.00₹525.00₹887.405
Jun ’24₹542.90
₹603.00
+11.1%
8.9%₹685.00₹525.00₹836.255
May ’24₹504.30
₹586.80
+16.4%
6.0%₹630.00₹525.00₹828.905
Apr ’24₹392.90
₹551.00
+40.2%
8.5%₹604.00₹485.00₹785.054
Mar ’24₹374.90
₹551.00
+47.0%
8.5%₹604.00₹485.00₹859.604
Feb ’24₹380.10
₹551.00
+45.0%
8.5%₹604.00₹485.00₹856.704
Jan ’24₹420.15
₹562.25
+33.8%
7.2%₹629.00₹525.00₹655.204
Dec ’23₹433.30
₹562.25
+29.8%
7.2%₹629.00₹525.00₹636.904
Nov ’23₹437.20
₹562.25
+28.6%
7.2%₹629.00₹525.00₹619.454

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

7D

-0.09%

1Y

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

7D

14.0%

1Y

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

7D

-4.9%

1Y

6.1%